Alphamab Oncology has announced that the Jiangsu Alphamab Pharmaceuticals has collaborated with the Insitut Pasteur of Shanghai, Chinese Academy of Sciences to manufacture, develop and distribute the Covid-19 Neutralizing Anti-Body across the globe.
According to the agreement both the Institut Pasteur Shanghai and Alphamab Oncology will form a joint research team to work on the covid-19 anti-body.
Almost 710 million across the globe have been diagnosed with the novel Covid-19 pandemic, but there are still no medicines or vaccines available in the market to treat the infection. The neutralizing anti-body will significantly help to target the protein on the surface to prevent the entry of covid-19 virus.
Founder, Chief Executive Officer and Chairman of Alphamab Oncology, Dr. Ting Xu said, “Since the end of 2019, COVID-19 has ravaged the world and has become the major global public health issue.”
“We plan to partner with Institut Pasteur Shanghai by leveraging our proprietary antibody technology platform, extensive experiences in antibody drug R&D and established manufacturing platform to accelerate the development of COVID-19 antibodies to combat COVID-19, prevent subsequent outbreaks and contribute to the further prevention and control of this epidemic,” Dr. Ting Xu further added.
Director General and Legal Representative of Institut Pasteur Shanghai, Dr. Hong Tang said, “Since the outbreak of the Coronavirus, the Institut Pasteur Shanghai has been focusing on R&D Projects including virus detection and origin tracing, antibody drug and vaccine, and has achieved quite a few progress.”
“This partnership with Alphamab Oncology on COVID-19 neutralizing antibody drug has demonstrated not only the innovation capability of our research and development team, but also a result of the reform of Chinese Academy of Sciences and the capable platform of Shanghai Science and Innovation Center. Our institute will collaborate with industry players to accelerate drug development and contribute to the prevention and control of pandemic as soon as possible,” Dr. Hong Tang concluded.